Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 901–1,000 of 1,004
Liu, H., Zhang, Y., Zhang, Q., Zhang, T., & Lu, T. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812328 · Cited by 6
“Purine metabolism status had closely related to the expression of immune checkpoints [16,17].”
BackgroundHu, X., Ma, C., & Kong, X. (2024) · Cancer Screening and Prevention · doi:10.14218/csp.2024.00017 · Cited by 5
Özkan, S., Bay, V., Acar, M. C., & Yalçın, S. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1463301 · Cited by 7
Influence of gut microbiota on systemic immune responses and cancer immunotherapy
Murakonda, S. P., Balusu, S., Chava, H., Murakonda, A. B., Polneedi, R., Bodduluri, S., Gupta, S. C., & Challagundla, K. B. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.005 · Cited by 6
Hannawayya, R., Puentes, R., Mirzadzare, N., Cirone, K. M., Amin, H. J., Soraisham, A. S., Alshaikh, B. N., Thomas, S., & Cobo, E. R. (2025) · Pediatric Research · doi:10.1038/s41390-025-03882-9 · Cited by 6
Li, J., Jia, J., Teng, Y., Wang, X., Xia, X., Song, S., Zhu, B., & Xia, X. (2025) · Food & Function · doi:10.1039/d4fo05449k · Cited by 5
Wang, H., Baba, Y., Hara, Y., Toihata, T., Kosumi, K., Harada, K., Iwatsuki, M., Miyamoto, Y., & Baba, H. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16288-4 · Cited by 5
“24,28 In the meantime, the microbiome has also shown potential cross-talk with skeletal muscle, termed the ‘gut-muscle axis’, 29 but with limited clinical evidence.”
Silva, C. A. C., Almonte, A. A., & Zitvogel, L. (2025) · Biomolecules · doi:10.3390/biom15040504 · Cited by 6
“Microbial-related metabolites such as polyamines and inosine influence T cell immunity [39,40], restore tissue-resident memory T cells [41], and enhance fatty acid oxidation that leads to CD8 + T cell activation [42].”
Weng, X., Huang, Y., Fu, Z., Liu, X., Xie, F., Wang, J., Zhu, Q., & Zheng, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582203 · Cited by 7
“In addition, recent studies have shown that abnormal nucleotide metabolism may also alter the immune response of the tumor microenvironment (TME), further promoting the immune escape and drug resistance of the tumor (14).”
Microbial metabolite ammonia disrupts TGF-β signaling to promote colon cancer
Bhowmick, K., Yang, X., Mohammad, T., Xiang, X., Molmenti, C. L. S., Mishra, B., Dasarathy, S., Krainer, A. R., Hassan, M. I., Crandall, K. A., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108559 · Cited by 6
“The relationship among diet, the microbiome, and the immune system is increasingly considered as a signi fi cant factor in immunity and cancer (37 – 39).”
Matsumoto, Y., Hitaka, Y., Hirata, H., Yamamoto, Y., Kobayashi, K., Isoyama, N., Matsubara, T., Watanabe, K., Mizukami, Y., Nakagawa, S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324814 · Cited by 5
Zhu, X., Fang, Z., & Chen, J. (2025) · LWT · doi:10.1016/j.lwt.2025.118081 · Cited by 5
Yang, J., Shi, J., Xu, W., Mu, J., Chang, Y., Zhang, X., & Wang, X. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120458 · Cited by 5
Bacterial-adjuvant liquid metal nanocomposites for synergistic photothermal immunotherapy
Sang, N., Iwata, S., Qi, Y., & Miyako, E. (2025) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-025-01434-7 · Cited by 5
“As a gram-positive bacterium, Lacto effectively stimulates immune responses in cancer therapy through its abundance of pathogen-associated molecular patterns (PAMPs), including peptidoglycan and teichoic acids [39, 41].”
Li, M., Zhang, X., Lu, J., Xiang, J., Wu, J., Zheng, M., Yang, S., He, L., & Shao, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07435-w · Cited by 5
“Inosine promotes neuroregeneration and modulates T cell activity [37, 38].”
Assessing the Resolution of Methyltransferase-Mediated DNA Optical Mapping
D’Huys, L., Vitale, R., Ruppeka‐Rupeika, E., Goyvaerts, V., Ruckebusch, C., & Hofkens, J. (2021) · ACS Omega · doi:10.1021/acsomega.1c01381 · Cited by 6
Zhang, Y., Zhou, Z., Xiao, W., Tang, Y., Guan, W. P., Wang, J., Shu, F., Shen, J., Gu, S., Zhang, L., et al. (2022) · Molecules · doi:10.3390/molecules27092994 · Cited by 5
“pneumoniae infections [27,28], little attention has been paid to the pathogen metabolism, which interacts with other microorganisms or hosts in various ways.”
BackgroundWen, X., Ye, X., Yang, X., RuJin, J., Qian, C., & Wang, X. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02995-5 · Cited by 5
“This was in comparison to models that were germ free or models that were monocolonized with Colidextribacter or Prevotella species [107].”
ResultMyeloid vitamin D receptor regulates Paneth cells and microbial homeostasis
Bakke, D., Zhang, J., Zhang, Y., Ogbu, D., Xia, Y., & Sun, J. (2023) · The FASEB Journal · doi:10.1096/fj.202202169rr · Cited by 5
Evidence on the importance of gut microbiota for the immune system
Surapsari, J., Oktarina, M. D., Sundjaya, T., & Wasito, E. (2023) · World Nutrition Journal · doi:10.25220/wnj.v06.s2.0002 · Cited by 5
“46,47 There is also a direct connection between B. adolescentis , a common commensal bacteria found in the human colon, and the production of homologous Th17s.”
BackgroundLearning from the microbes: exploiting the microbiome to enforce T cell immunotherapy
Staudt, S., Ziegler-Martin, K., Visekruna, A., Slingerland, J. B., Shouval, R., Hudecek, M., van den Brink, M. R. M., & Luu, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269015 · Cited by 5
“While their production within the host can be modulated and utilized by diet, metabolite libraries might be valuable to screen and identify novel tools to improve ACTs and immune cell engineering (7, 79, 84, 96, 103).”
BackgroundKoh, H., Kim, J., & Jang, H. (2025) · BioData Mining · doi:10.1186/s13040-025-00422-3 · Cited by 6
Cross communication of diet-microbiome-immune interactions in cancer immunotherapy
Zhou, C., & Fang, J. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100806 · Cited by 6
“Multiple research efforts have highlighted that microbial community could regulatepatients’ sensitivity to immunotherapy through interacting with both endogenous and exogenous metabolites, leading to crosstalk between metabolic network and immune microenvironment, thereby impacting anti-tumor immune response and toxic…”
BackgroundImpact of the gut microbiome on skin fibrosis: a Mendelian randomization study
Zhao, Z., Xu, Z., Lv, D., Rong, Y., Hu, Z., Yin, R. H., Dong, Y., Cao, X., & Tang, B. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1380938 · Cited by 5
Bacterial strains augment cancer therapeutics
Hall, L. J., & Robinson, S. D. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00871-6 · Cited by 5
Álvarez‐López, A. I., Ponce‐España, E., Cruz‐Chamorro, I., Santos‐Sánchez, G., Bejarano, I., Álvarez‐Sánchez, N., Lardone, P. J., & Carrillo‐Vico, A. (2025) · MedComm · doi:10.1002/mco2.70228 · Cited by 7
Pan-Cancer Insights: A Study of Microbial Metabolite Receptors in Malignancy Dynamics
Dovrolis, N., Spathakis, M., Collins, A. R., Pandey, V. K., Uddin, M. I., Anderson, D. D., Kaminska, T., Paspaliaris, V., & Kolios, G. C. (2024) · Cancers · doi:10.3390/cancers16244178 · Cited by 4
Insights into the gut microbiome-metabolite dynamics in breast cancer
Manzoor, H., & Kayani, M. U. R. (2025) · Gut Microbes Reports · doi:10.1080/29933935.2025.2483446 · Cited by 4
Extracellular Inosine Induces Anergy in B Cells to Alleviate Autoimmune Hepatitis
Cui, N., Qian, Q., Zhou, Y., Zhang, H., Zhang, H., Wang, B., Li, Y., Wang, Q., Lian, M., You, Z., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101539 · Cited by 4
“18,19,35 39 Importantly, we here reported that extracellular inosine treatment restores B cell homeostasis by increasing the anergic B cell subpopulation and reducing the propotion of ASCs, as demonstrated through both in vivo and in vitro experiments.”
Mechanical cues shaping cancer cell-microbiota interaction dynamics in tumor progression
Zhou, Y., Zhou, X., Zhu, X., Xu, F., & Li, F. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102612 · Cited by 7
Yu, Y., Park, S. Y., Jeon, J., Lee, S.-H., Kim, H., Seo, D., Park, M., Park, E., Kim, J. Y., Cho, S.-J., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02992-4 · Cited by 4
“For instance, Bifidobacterium enhances the efficacy of immune checkpoint inhibitors by producing metabolites [10, 11].”
Wu, D., Fan, Y., Zhang, M., Wang, X., He, X., Guo, X., Liu, Y., Cao, C., & Deng, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1598436 · Cited by 9
“In colorectal cancer mice, L. johnsonii combined with CTLA-4 inhibitors reduced tumor volume by 85% compared to CTLA-4 inhibitors alone (30).”
Microbiome and immunotherapy in bladder cancer: The missing link
Bourgi, A., Bruyère, F., & Rüsch, E. (2025) · The French Journal of Urology · doi:10.1016/j.fjurol.2025.102922 · Cited by 5
Koopman, N., Jaspers, Y. R. J., van Leeuwen, P. T., Chronas, K., Yim, A. Y. F. L., Diederen, K., Velde, A. A. T., Roseboom, W., Kindermann, A., Benninga, M. A., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00984-7 · Cited by 4
The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy
Hao, M., Xu, H., Li, M., & Jiao, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1634703 · Cited by 5
Zheng, Y., Lin, W., Chen, J.-Q., Wei, X., Huang, J., Xu, Y., Yang, M., Zhang, Q., Zuo, Z., Yang, Z., et al. (2025) · MedComm · doi:10.1002/mco2.70316 · Cited by 5
“Lactobacillus johnsonii can significantly improve the efficacy of ICI in four cancer mouse models [42].”
Gao, P., Pang, S., Wang, Q., Tang, Y., Li, Q., Zhang, W., Nie, C., Ma, X., & Niu, J. (2025) · Microorganisms · doi:10.3390/microorganisms13091993 · Cited by 4
“These strains enhance the efficacy of checkpoint blockade immunotherapy, significantly improving immune checkpoint inhibitor outcomes in four murine cancer models [65].”
Shi, J., Zhang, Y., Wei, X., Liu, X., Li, Z., Huang, H., Cheng, L., Lin, Z., Zhang, B., & Yang, Q.-Q. (2025) · Nano Research · doi:10.26599/nr.2025.94908003 · Cited by 5
Guardians in the Gut: Mechanistic Insights into a Hidden Ally Against Triple-Negative Breast Cancer
Jaye, K. M., Alsherbiny, M. A., Chang, D., Li, C. G., & Bhuyan, D. J. (2025) · Cancers · doi:10.3390/cancers17193248 · Cited by 4
“The potential application of inosine as an antiproliferative agent is based on the observation that the introduction of inosine-producing bacterial species can increase overall host immunity and the efficacy of immune checkpoint blockade therapies [35].”
InfluentialHuo, F., Liu, Q., Zhang, S., Liu, X., Lv, S., Zhao, M., Liu, Y., Zhu, X., Huang, C., Feng, S., et al. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01552-8 · Cited by 7
ADA1-Driven Metabolic Refueling Enhances CAR T Cell Therapy for Solid Tumors
Song, A. W., & Song, X. (2025) · Cancers · doi:10.3390/cancers18010034 · Cited by 4
“Inosine, unlike adenosine, does not strongly activate T cell inhibitory receptors, and it can serve as an alternative carbon source, entering glycolytic and pentose phosphate pathways to support energy generation and biosynthesis under conditions of glucose restriction [25,93].”
Ronchi, F., Hinterbrandner, M., Rubino, V., Römmele, M., Chiorazzo, T., Mooser, C., Ganal-Vonarburg, S. C., McCoy, K. D., Bhatia, R., Macpherson, A. J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116753 · Cited by 4
Self-citationMicrobiome-modulated immunotherapy in oncology: Current applications and future prospects
Liu, Y., Miao, K., & Yang, X. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.01.001 · Cited by 4
Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy
Li, F., Qiao, L., Liang, X., Zhang, Y., Liang, N., Xie, J., Deng, G., Hao, Y., Hu, P., Wu, X., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71575 · Cited by 6
Wu, Q., Zhou, Y.-R., Chen, Z.-R., Liu, M.-X., Liu, M.-X., Liu, Y.-F., Li, Z., Zhao, Q.-R., Zhang, Y.-Q., Zhang, H., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105230 · Cited by 5
Profiling biological effects of microbiome metabolites via machine learning
Chung, H. A., Fralish, Z., Tu, T., & Reker, D. (2026) · iScience · doi:10.1016/j.isci.2026.115282 · Cited by 4
“5 However, given the complexity of the immune system and the microbiome, our understanding of the interplay between microbiome metabolites and the immune system continues to be sparse.”
Decoding the gut microbiota-immune dialogue: from bidirectional axis to therapeutic applications
Liu, Y., Chen, C., Liu, H., Wang, W., Zhou, X., Guo, M., Zhao, J., Zeng, Z., & Xu, L. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04376-4 · Cited by 4
“Specific symbiotic bacteria, such as Bacteroides fragilis , or their metabolites (SCFAs, Trp metabolites, and BAs) can promote the function of immunosuppressive cells, suppress inflammatory responses, and thereby enhance the efficacy of immunotherapy [290–292] ( Fig.”
Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies
Yu, Y., Guo, Z., Luo, Z., Dian, Y., Yang, X., Chen, X., Zeng, F., & Deng, G. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00473-w · Cited by 5
“Inosine, produced by intestinal Bifidobacterium pseudolongum ( B. pseu-dolongum ), systemically induces Th1-regulating gene expression in CD4 + T cells [148].”
Bernardes, E. V. T., Glatthardt, T., Gutierrez, M. W., Nguyen, W. N. T., Mercer, E. M., Ramay, H. R., Thomson, C. A., Halim, T., Gopalakrishnan, N., MacConnell, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74417-x · Cited by 5
“Isolation of mLN immune cells mLN immune cell isolation was performed as previously described 127 , with small modi fi cations. mLN were cleaned of any fat and connective tissue and digested for 25min, at 37°C in digestion medium (RPMI supplemented with 1 mg/ml Collagenase IA [Sigma] and 30 U/ml…”
Self-citationLin, Z., Mu, S., Zhang, W., Guo, Y., Dong, C., Song, L., Zhang, H., Wu, R., Luo, P., & Liang, L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102428 · Cited by 4
Review Article a Multidisciplinary Evaluation for Advanced Supportive Care of Breast Cancer Patients
Petrone, A., Carlesimo, M., Fortuna, M. C., Peccatori, F. A., Codacci-Pisanelli, G., Barbara, R., Cruciani, S., Serra, P. A., Maioli, L., Maioli, M., et al. (2022) · Breast Care · doi:10.1159/000528280 · Cited by 6
Visual analysis of colorectal cancer and gut microbiota: A bibliometric analysis from 2002 to 2022
Long, D., Mao, C., Zhang, Z., Zou, J., & Zhu, Y. (2023) · Medicine · doi:10.1097/md.0000000000035727 · Cited by 4
“[85,86] Lactobacillus rhamnosus was confirmed to enhance immunotherapy efficacy through the cGAS/STING/TBK1/IRF7 axis in dendritic cells.”
BackgroundGutierrez, M. J., Niño, G., Gualteros, S. M. R., Mondell, E., Chorvinsky, E. A., Bhattacharya, S., Bera, B. S., Welham, A., Hong, X., & Wang, X. (2023) · ERJ Open Research · doi:10.1183/23120541.00693-2023 · Cited by 4
“Uric acid precursors, such as inosine, enhance Th1 differentiation of naïve T-cells and interferon (IFN)- γ release, critical for host defence against intracellular pathogens, including viruses [36, 38].”
BackgroundEngineering immune response to regulate cardiovascular disease and cancer
Rani, D., Kaur, S., Shahjahan, Dey, J. K., & Dey, S. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.12.004 · Cited by 6
Microbiome dynamics in immune checkpoint blockade
Kim, C. W., Kim, H.-J., & Lee, H. K. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.013 · Cited by 5
Lin, T., Shih, T., & Lin, C. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13772 · Cited by 4
Xu, J., Tian, Y., Hu, D., Xi, Y., & Yang, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.85 · Cited by 5
Identifying and Filling the Chemobiological Gaps of Gut Microbial Metabolites
Orgaz, C., Sánchez-Ruiz, A., & Colmenarejo, G. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00903 · Cited by 3
Personalised medicine based on host genetics and microbiota applied to colorectal cancer
González, A., Badiola, I., Fullaondo, A., Rodríguez, J., & Odriozola, A. (2024) · Advances in genetics · doi:10.1016/bs.adgen.2024.08.004 · Cited by 4
Luca, A. D., Bennato, F., Ianni, A., Martino, C., Henry, M. A., Meleady, P., & Martino, G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311539 · Cited by 4
Hu, Z., Zhu, H., Jin, Y., Liu, P., Yu, X., & Zhang, Y.-R. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i2.101611 · Cited by 5
How Do Microbial Metabolites Interact with Their Protein Targets?
Astigarraga, M., Sánchez-Ruiz, A., Diop-Aw, A., Quintero, R., & Colmenarejo, G. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01875 · Cited by 4
Functional regulation of cytotoxic T Cells by gut microbial metabolites
Kim, C. H. (2025) · Gut Microbes Reports · doi:10.1080/29933935.2025.2454002 · Cited by 6
“129 Thus, these metabolites, produced by both microbes and host cells, also have the potential to regulate CTLs.”
Wu, Y., Zhang, Y., Zhang, W., Huang, Y., Lu, X., Shang, L., Zhou, Z., Chen, X., Li, S., Cheng, S., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05014-4 · Cited by 4
The intestinal microbiota and cellular therapy: implications for impact and mechanisms
Xie, J., & Smith, M. M. (2024) · Blood · doi:10.1182/blood.2024024219 · Cited by 4
Teng, N. M. Y., Malfettone, A., Dalby, M. J., Kiu, R., Seki, D., Robinson, T., Gión, M., Bermejo, B., Pérez-García, J. M., Prat, A., et al. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2024.49 · Cited by 7
The progress on the relationship between gut microbiota and immune checkpoint blockade in tumors
Jiang, H., Ye, Y., Wang, M., Sun, X., Sun, T., Chen, Y., Li, P., Zhang, M., & Wang, T. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2212526 · Cited by 5
“…inhibit NLRP3 activity (Fiorucci et al., 2018; Park et al., 2015), thereby downregulating TNF-α and IL-12 in dendritic cells and monocytes, and increasing production of IL-10 by macrophages, thereby disrupting the pro-inflammatory function of immune cells (Bachem et al., 2019; Mager et al., 2020).”
Gut microbiota: key facilitator in metastasis of colorectal cancer
Yu, S., Wang, S., Xiong, B., & Peng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1270991 · Cited by 6
Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
Fidelle, M., Lebhar, I., Zitvogel, L., & Kroemer, G. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2224679 · Cited by 4
Dravillas, C. E., Williams, N. F., Husain, M., Hoyd, R., Hussein, A., Meara, A. S., Lynn, M., Bibi, A., Conrad, B., Lepola, N., et al. (2025) · medRxiv · doi:10.1101/2025.01.30.25321413 · Cited by 5
“The microbiome has been associated with ICI response via several mechanisms, including antigen mimicry [24], innate immune activation (for example, via toll-like receptors [TLRs]) [25], and small-molecule secretion distal to [26] and within [27] the tumor.”
Crawford, M. S., Ulu, A., Ramirez, B. M., Santos, A. N., Chatterjee, P., Canale, V., Manz, S., Lei, H., Soriano, S. M., Nordgren, T. M., et al. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4808 · Cited by 4
“These species can convert leucine into SCFAs like isobutyrate and isovalerate, which are important for water and electrolyte balance in the colon (Mager et al. 2020).”
Yu, J., Zhu, H., Yu, X., Liu, Y., Zhang, J., Jiang, L., & Zhang, X. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110017 · Cited by 4
Che, K., Qian, D., Cui, S., & Xie, F. (2025) · Health Science Reports · doi:10.1002/hsr2.71206 · Cited by 4
Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine
Li, X., Yeganeh, M., Sinclair, G. B., Mwenifumbo, J. C., Jacob, K. J., Arbour, L. T., Lehman, A., Rakić, B., Vaz, F. M., Horvath, G. A., et al. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00523-2 · Cited by 4
The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
Ni, Z., & Ye, D. (2025) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2025.02719 · Cited by 6
Nanotechnology – Microbiota synergy in cancer immunotherapy
Yang, J., Wang, J., Li, J., & Cui, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105018 · Cited by 5
Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential
He, J., Tan, H. Z., Qiu, Y., Dan, Y., Wan, Q., Li, L., Wu, J., Song, Q., Chen, H., & Xu, B. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101963 · Cited by 5
Unraveling the microbiome’s role in breast cancer progression and treatment response
Taki, A. G., Shareef, A., Arora, V., Oweis, R. J., Jyothi, S. R., Singh, U., Sahoo, S., Chauhan, A. S., Alimova, F., Sameer, H. N., et al. (2025) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2025.101264 · Cited by 3
Honcharyuk, I., Caridi, B., Pinco, P., Ferri, S., Giani, A. D., Baeri, A., Amoroso, C., Massironi, S., & Facciotti, F. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2602537 · Cited by 3
“Tumor-associated microorganisms can be recognized by the host immune system, activating local antitumor immunity and improving immunotherapy outcomes [24].”
Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer
Newsome, R. C., Liu, H., Agbodzi, B., Gharaibeh, R. Z., Zhou, L., & Jobin, C. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102519 · Cited by 5
“30 70 Tryptophan metabolites like indole derivatives can be uniquely microbially derived and promote anti-tumor immunity, as in the case of indole-3-propionic acid, which can activate progenitor exhausted CD8 + T cells (Tpex cells), improving response to ICI in mice.”
The Mediating Role of the Gut Microbiome in the Nutritional Prevention of Cancer
Chambial, P., Thakur, N., Kumar, U., & Gupta, S. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.101301 · Cited by 4
Wang, S., Huai, S., Yuan, Z., Ji, T., Xu, Y., Ren, Y., Qian, N., Sun, S., & Li, J. (2026) · hLife · doi:10.1016/j.hlife.2025.12.006 · Cited by 4
“INO, a bacterial metabolite derived from Bifidobacterium pseudolongum and A. muciniphila [27], emerged as a key mediator of BBR’s effects.”
InfluentialMa, P.-J., Li, M., Hu, W., Ding, Y., Liang, Y.-K., Chen, L., Wang, X., Pan, Y., & Wang, Y. (2026) · Microbiome · doi:10.1186/s40168-026-02348-2 · Cited by 4
“…administration of Lactobacillus rhamnosus CRL1505 , Lactobacillus rhamnosus M21 , and Lactobacillus rhamnosus could induce immune responses against respiratory syncytial virus, influenza virus, or pneumococcal infections, thereby enhancing pathogen clearance and reducing lung tissue damage [17–20].”
Lv, D., Wang, S., Xiao, W., Xu, J., & Jin, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189562 · Cited by 4
He, Q., Hong-ji, W., Guo, M., Ye, R., Li, H., & Zhang, Q. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112455 · Cited by 3
Kang, W., Zhang, Z., Li, W., Zhang, Q., Li, N., Jiang, Y., Zhang, J., & He, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773002 · Cited by 3
Gut microbial metabolites and immune-related diseases
Guo, J., Yin, X., Wang, K., & Jiang, C. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00031-7 · Cited by 6
Elsheikh, M., Ibrahim, M. A., Fares, S., Bhongade, M., Adhem, K., Ramirez-Morales, X. I., Kaseb, A. O., Petrosino, J. F., Hassan, M. M., & Jalal, P. K. (2026) · Cancer Medicine · doi:10.1002/cam4.71738 · Cited by 4
The gut microbiota alleviates depression by remodeling gut-brain energy metabolism
Lu, C.-L., Ren, J., Lei, Y., Lian, X.-Y., Jiang, H.-T., Guo, F., Chen, L.-Y., Mo, J., Mao, H., Fan, J., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.002 · Cited by 7
From Microbial Ecology to Functional Components in Microbe–Host Interactions
Wang, T., Wang, Z., Yang, X., & Zhang, L. (2026) · Biology · doi:10.3390/biology15080635 · Cited by 3
“Pre-clinical models suggest that inosine derived from Bifidobacterium pseudolongum may enhance Th1 and effector T cell responses through adenosine A2A receptor signaling on T cells under co-stimulatory conditions, thereby improving tumor responses to immune check-point blockade [221].”
Intratumoral Microorganisms in Tumors: Current Understanding and Emerging Therapeutic Strategies
Zhang, H., Du, Z., Lu, P., Jiang, A., Guo, Y., Liu, Y., Song, Z., Dai, B., & Zhang, W. (2026) · MedComm · doi:10.1002/mco2.70754 · Cited by 6
“Engineered microbes, metabolite-based interventions, micro-biome remodeling, or combination with therapy are highlighting the preclinical potential in reprogramming local immunity to enhance antitumor response [ 8, 9 ].”
Sun, Q., Li, X., Wu, J., Zhang, J., Zhu, Y., & Dong, Y. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105382 · Cited by 3
Gut microbiota and metabolic control of immune checkpoint blockade in cancer
Gladstone, J. L., & Sonnenberg, G. F. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.04.018 · Cited by 4
Integration of donor microbiota following FMT correlates with anti-PD-1 response in melanoma
Fessler, J. L., Olm, M. R., Engleman, E. G., & Sonnenburg, J. L. (2026) · Nature Communications · doi:10.1038/s41467-026-73465-7 · Cited by 7
“The transfer of speci fi c microbes could mediate response, which may exert anti-cancer or immunomodulatory effects through the production of microbial metabolites (e.g., short-chain fatty acids 31 – 33 and inosine 34 ) or via direct interactions with host immune cells.”
Intratumoral Microbiota in Tumor: Current Understandings and Future Perspectives
Chen, J., Bai, Y., Shen, L., Ying, J., Xu, J. Q., Tang, J., & Bao, Y.-J. (2026) · MedComm · doi:10.1002/mco2.70825 · Cited by 3
“Subsequent independent studies across multiple models reached concordant conclusions, systematically supporting that micro-biome interventions can broadly potentiate immunotherapy and establishing a conceptual basis for “probiotic–immunotherapy synergy” [ 186, 251 ].”
Microbiome and cancer: mechanistic insights, diagnostic potential, and therapeutic strategies
Kumar, V., Chaudhary, A., Gautam, M., Verma, P., & Singh, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1844436 · Cited by 3
“…Burkholderia cepacia ( B. cepacia ), Bifidobacterium pseudolongum ( B. pseudolongum ), Lactobacillus johnsonii ( L. johnsonii ), Olsenella spp., and E. faecium have been shown to promote antitumor immunity in anti-CTLA-4-treated mice (Griffin et al., 2021; Mager et al., 2020; Vétizou et al., 2015).”
InfluentialIntestinal colonization regulates systemic anti-commensal immune sensitivity and hyperreactivity
Burkhard, R., Koegler, M., Brown, K., Wilson, K., Mager, L. F., Zucoloto, A. Z., Thomson, C. A., Nanjundappa, R. H., Skalosky, I., Ahmadi, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1030395 · Cited by 5
“For example, short chain fatty acids (SCFA) such as butyrate or acetate promote local regulatory T cell induction and microbiota-derived inosine has been shown to be able to promote systemic anti-tumor responses (1, 23).”
BackgroundSelf-citationHuang, R., Yao, Y., Tong, X., Wang, L., Qian, W., Lu, J., Zhang, W., Liu, Y., Wang, S., Xian, S., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00135-23 · Cited by 3
“Relatively, plenty of Akkermansia muciniphila helped enhance ICI efficacy in the presence of IL-12 in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and urothelial cancer (18), while A. muciniphila also produced inosine, which might improve ICI effects (89).”
BackgroundEfficacy and regulatory strategies of gut microbiota in immunotherapy: a narrative review
Sang, Y., Zheng, K., Zhao, Y., Liu, Y., Zhu, S., Xie, X., Shang, L., Liu, J., & Li, L. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-316 · Cited by 4
“A team of researchers at the University of Calgary’s Cumming School of Medicine has found that Bifidobacterium pseudomallei , Lactobacillus johnsonii , and Serratia marcescens can enhance the immune system’s ability to recognize and “wipe out” cancer cells (56) .”
Fu, J., & Zheng, H. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1403825 · Cited by 3
“Bifidobacterium can also enhance the efficacy of ICIs in cancer mice by producing adenosine (Mager et al., 2020).”
Background
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.